Entity

Time filter

Source Type


Urakami K.,Shizuoka Cancer Center Research InstituteShizuoka | Shimoda Y.,SRL IncTokyo | Ohshima K.,Shizuoka Cancer Center Research InstituteShizuoka | Nagashima T.,SRL IncTokyo | And 10 more authors.
Biomedical Research (Japan) | Year: 2016

Next-generation DNA sequencing (NGS) of the genomes of cancer cells is contributing to new discoveries that illuminate the mechanisms of tumorigenesis. To this end, the International Cancer Genome Consortium and The Cancer Genome Atlas are investigating novel alterations of genes that will define the pathways and mechanisms of the development and growth of cancers. These efforts contribute to the development of innovative pharmaceuticals as well as to the introduction of genome sequencing as a component of personalized medicine. In particular, chromosomal translocations that fuse coding sequences serve as important pharmaceutical targets and diagnostic markers given their association with tumorigenesis. Although increasing numbers of fusion genes are being discovered using NGS, the methodology used to identify such fusion genes is complicated, expensive, and requires relatively large samples. Here, to address these problems, we describe the design and development of a panel of 491 fusion genes that performed well in the analysis of cultured human cancer cell lines and 600 clinical tumor specimens. © 2016, Biomedical Research Foundation. All right reserved. Source


Ono A.,Shizuoka Cancer CenterShizuoka | Murakami H.,Shizuoka Cancer CenterShizuoka | Serizawa M.,Shizuoka Cancer Center Research InstituteShizuoka | Wakuda K.,Shizuoka Cancer CenterShizuoka | And 9 more authors.
Lung Cancer | Year: 2016

A 57-year-old male current smoker was diagnosed with an aggressive variant of ALK-rearranged inflammatory myofibroblastic tumor (IMT) arising in the pleural cavity. First line treatment with ASP3026 was initiated at a dose of 125 mg once daily. A follow-up CT scan revealed drastic regression of the pleural lesion. After disease progression with ASP3026 treatment, LDK378 (ceritinib) was initiated at a dose of 750 mg once daily. A follow-up CT scan revealed a second drastic regression of the pleural lesion. Furthermore, it is noteworthy that this case represents the use of serum hyaluronan levels to assist in monitoring of treatment efficacy in an IMT. Herein, we present the first case of a patient with a highly aggressive ALK-rearranged IMT arising in the pleural cavity, who showed both initial and subsequent drastic response to two ALK inhibitors while being monitored for serum hyaluronan. © 2016 The Author(s) Source

Discover hidden collaborations